Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
12,958 total articles
VAALCO Energy announced successful drilling results offshore Gabon and onshore Egypt, with the Ebouri-5H well producing over 8,000 gross barrels of oil per day and the HE-9 well in Egypt exceeding predrill production expectations. The company continues its drilling campaign with plans to reduce operational costs by utilizing natural gas and aims to…
IQE plc and Tower Semiconductor announced a multi-year agreement for the supply of Indium Phosphide (InP) epiwafers to support next-generation optical connectivity solutions in AI-driven data center infrastructure. The collaboration includes technology development for high-speed optical transceivers and modulators, with minimum purchase and supply …
Magnera Corporation announced the sale of its Caerphilly, UK operations, which produce metallized paper for premium labels, gift wrap, and food packaging, to Polyart Group, a portfolio company of Prudentia Capital. The sale follows a strategic review aiming to optimize Magnera's manufacturing technologies and product markets. Magnera will continue …
At the EHA2026 Congress, Ascentage Pharma presented multiple positive clinical updates for its core assets olverembatinib and lisaftoclax in treating hematologic cancers such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Data highlighted effective responses, favorable safety profiles,…
Zymeworks Inc. announced new Phase 1 clinical trial data for their antibody-drug conjugate ZW191 targeting folate receptor alpha in patients with platinum-resistant ovarian cancer and endometrial cancer. The data demonstrate high confirmed objective response rates (78.6% in FRα-positive ovarian cancer and 47.4% in FRα-negative cases) and durable re…
Crinetics Pharmaceuticals presented positive Phase 2 clinical data showing their investigational oral drug Atumelnant significantly reduced androgen levels while enabling glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia (CAH). Additionally, initial Phase 1b/2a trial results in ACTH-dependent Cushing’s syndrome de…
Crinetics Pharmaceuticals presented up to two years of data from PATHFNDR-1 and PATHFNDR-2 open-label extension studies showing that PALSONIFY (paltusotine), an oral somatostatin receptor agonist, maintains stable IGF-1 levels, controls acromegaly symptoms, and stabilizes or reduces pituitary tumor volume. The data confirmed durable disease control…
Celldex Therapeutics presented long-term Phase 2 data demonstrating that barzolvolimab treatment yields rapid, significant, and durable improvements in angioedema symptoms among patients with moderate to severe chronic spontaneous urticaria (CSU). Up to 64% of patients remained angioedema-free seven months post-treatment, indicating potential disea…
Mineralys Therapeutics presented post hoc proteomic analysis data indicating that lorundrostat, an investigational aldosterone synthase inhibitor, significantly reduces biomarkers linked to heart failure risk in patients with uncontrolled hypertension. These findings support lorundrostat's therapeutic potential and coincide with ongoing FDA review.…
Upstream Bio presented new responder analyses from its Phase 2 VIBRANT trial demonstrating that Verekitug, a TSLP receptor antagonist administered every three months, achieved clinically meaningful improvements in nasal polyp score and multiple key symptoms in a significant majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP)…
Celldex Therapeutics reported positive Phase 1 clinical trial results for CDX-622, a novel bispecific antibody targeting soluble stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP) pathways. The study demonstrated rapid, dose-dependent mast cell depletion and TSLP inhibition with good tolerability and safety in healthy participants, supp…
Legend Biotech presented encouraging early clinical data for LB2501, their investigational in vivo CD19/CD20 dual-targeting CAR-T therapy, showing 100% objective response and 83.3% complete response rates at the higher dose in a Phase 1 trial for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy demonstrated dose-dependent CAR-T expansio…
Ascendis Pharma announced positive Phase 3 PaTHway trial results demonstrating that TransCon PTH provides sustained normalization of biochemical markers, improved kidney function, bone density, and quality of life in adults with hypoparathyroidism over 182 weeks. The treatment enabled patients to discontinue conventional therapies such as active vi…
Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…
Rhythm Pharmaceuticals announced encouraging interim six-month data from their Phase 2 trial of setmelanotide in patients with Prader-Willi Syndrome (PWS), demonstrating clinically meaningful reductions in BMI, fat mass, hyperphagia scores, and anxiety measures. These results strengthen the case for advancing setmelanotide, an MC4R agonist, into Ph…
Intellia Therapeutics reported additional positive results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an in vivo CRISPR gene-editing therapy for hereditary angioedema (HAE). The treatment demonstrated an 87% reduction in monthly HAE attacks versus placebo and a favorable safety profile. The data were presented at EAACI …
Arcadia Biosciences (Nasdaq: RKDA) successfully closed a $4 million private placement by issuing common stock and preferred investment options at $1.03 per share, with gross proceeds intended for working capital and general corporate purposes. The offering was conducted under Section 4(a)(2) of the Securities Act and accompanied by registration rig…
Belite Bio, a clinical-stage US biopharmaceutical company, has completed the rolling submission of its New Drug Application to the FDA for tinlarebant, an investigational oral therapy targeting Stargardt disease type 1 (STGD1), a rare inherited retinal disorder with no approved treatments. The submission leverages multiple expedited regulatory desi…
ROMA Green Finance has announced the creation of a dedicated investment vertical focused on Artificial Intelligence and High-Performance Computing infrastructure, emphasizing energy-efficient, low-carbon digital assets paired with behind-the-meter power generation. This move extends their sustainable finance and ESG advisory mandate into digital in…
Heartland Express, Inc. announced the declaration of a regular quarterly cash dividend of $0.02 per share payable on July 6, 2026, marking the company's 92nd consecutive quarterly dividend payment. The total dividend payout is estimated at $1.6 million based on approximately 78 million shares outstanding, continuing a dividend program that began in…
Traws Pharma announced the deferment of its planned Phase 2a human influenza challenge study for its lead antiviral candidate, tivoxavir marboxil (TXM), due to a negative review by the UK's MHRA. Despite the setback, the company remains committed to advancing TXM and other back-up influenza antiviral compounds with improved profiles, highlighting t…
Lotus Technology Inc. announced progress on its strategic acquisition of Lotus UK aimed for 2026 closure, as part of its Focus 2030 strategy to unify brand and enhance operational efficiency. The company is temporarily suspending earnings releases for Q1 and Q3 of 2026 to prioritize acquisition compliance and integration, while continuing to report…
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company aims to eliminate duplicate exchange fees, reduce legal and accounting expenses, optimize financing initiatives, and simplify regulatory compliance by maintaining a single listing on t…
The Children's Place reported a Q1 2026 net sales decline of 11.1% to $215.2 million, with an operating loss of $42.2 million and net loss of $53.2 million. The company is implementing strategic initiatives focusing on customer experience, brand strength, financial targets, and leadership amid challenging retail conditions and higher tariff costs. …
Black Hills Corp.'s Colorado electric utility has submitted a rate review application to the Colorado Public Utilities Commission seeking $26.7 million in additional annual revenue. This is to recover approximately $184 million invested since the last rate review, particularly aimed at improving reliability and strengthening the electric grid. The …
